We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 99.02%
2 Miscellaneous 0.97%
3 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FPRX
101
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$787K 0.01%
19,247
– –
INFI
102
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$772K 0.01%
580,400
– –
BDSI
103
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$620K 0.01%
210,021
– –
FLGT icon
104
Fulgent Genetics
FLGT
$563M
$599K ﹤0.01%
125,000
– –
TARA icon
105
Protara Therapeutics
TARA
$226M
$597K ﹤0.01%
7,465
– –
NVIV
106
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$580K ﹤0.01%
21
– –
MTEM
107
DELISTED
Molecular Templates, Inc.
MTEM
$505K ﹤0.01%
+4,827
New +$417K
TTOO
108
DELISTED
T2 Biosystems, Inc
TTOO
$420K ﹤0.01%
+20
New +$371K
CCXI
109
DELISTED
ChemoCentryx, Inc.
CCXI
$364K ﹤0.01%
49,064
– –
TMBR
110
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$171K ﹤0.01%
40
– –
TENX icon
111
Tenax Therapeutics
TENX
$69.6M
$126K ﹤0.01%
11
+7
+175% +$104K
BGMSP
112
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$98K ﹤0.01%
13,253
– –
BTX.WS
113
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$4K ﹤0.01%
20,084
– –
CRBP icon
114
Corbus Pharmaceuticals
CRBP
$156M
– –
-4,338
Closed -$820K
MCRB icon
115
Seres Therapeutics
MCRB
$50.3M
– –
-6,250
Closed -$1.41M
PTN
116
Palatin Technologies
PTN
$23.8M
– –
-1,640
Closed -$882K
RARE icon
117
Ultragenyx Pharmaceutical
RARE
$1.34B
– –
-25,000
Closed -$1.55M
CMRX
118
DELISTED
Chimerix, Inc.
CMRX
– –
-115,216
Closed -$628K
ALDR
119
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-217,328
Closed -$2.49M
BIVV
120
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-8,249
Closed -$496K
JUNO
121
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-50,000
Closed -$1.5M
ZGNX
122
DELISTED
Zogenix, Inc.
ZGNX
– –
-185,290
Closed -$2.69M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Baker Bros. Advisors held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Technology.

  • Baker Bros. Advisors's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Baker Bros. Advisors added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Baker Bros. Advisors's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Baker Bros. Advisors fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Baker Bros. Advisors opened 9 new positions and closed 9 in Q3 2017.
  • Baker Bros. Advisors's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.